Losartan potassium is a popular medication prescribed for managing high blood pressure and reducing the risk of strokes in patients with heart conditions. As with any medication, the brand or manufacturer can play an important role in the drug's quality and efficacy. Some well-regarded brands in the pharmaceutical industry known for producing reliable and effective losartan potassium include Merck & Co., Inc., the original developer under the brand name Cozaar, and major generic manufacturers like Teva Pharmaceuticals and Lupin Pharmaceuticals. Each of these companies has a track record of meeting stringent manufacturing standards, ensuring that patients receive a product they can trust for their health needs. To explore further details about these brands and others available in the market, check the comprehensive list below.
Illustration of losartan potassium
Best brands of losartan potassium in 2025
Cozaar
Cozaar, marketed by Merck & Co., Inc., is a renowned brand for losartan potassium, an angiotensin II receptor blocker primarily used to treat hypertension. It was the inaugural angiotensin II antagonist to be commercialized and is also available in generic form. The global losartan market, led by North America with over 40% market share, is anticipated to experience substantial growth, particularly with the Asia-Pacific region forecasted to exhibit the highest compound annual growth rate (CAGR) of 6.5% from 2024 to 2031. Cozaar's safety profile has been validated in over 3300 adult patients, demonstrating high tolerability with an adverse event rate comparable to placebo. The market valuation for losartan potassium is projected to reach USD 87.26 billion by 2031.
Losartan
Teva Pharmaceuticals is a leading producer of Losartan Potassium, with a significant market share in the global losartan market, which is estimated to be USD 1625.5 million in 2024 and is projected to grow at a CAGR of 4.50% from 2024 to 2031. In North America, Teva's losartan products hold a major market share, with a market size of USD 513.01 million in the United States alone in 2024, growing at a CAGR of 2.5% from 2024 to 2031. The company's losartan potassium tablets are widely used for treating hypertension, hypertensive patients with left ventricular hypertrophy, and nephropathy in Type 2 diabetic patients. Despite recalls due to impurities, Teva has maintained its reputation through prompt action and quality control measures. The global losartan potassium API market, where Teva is a key player, is expected to reach USD 2403.42 million by 2031, growing at a CAGR of 5.50%. For more detailed information on their recent recall and actions, please visit the Teva Pharmaceuticals latest news page.
Sandoz Losartan
Sandoz Losartan, produced by Sandoz Canada Inc., is a leading brand in the losartan potassium market, known for its efficacy in treating essential hypertension and left ventricular hypertrophy. The product is available in various strengths, including 25mg, 50mg, and 100mg tablets, and is often used concomitantly with thiazide diuretics. Sandoz Losartan has demonstrated antihypertensive effects in pediatric patients aged 6 to 16 years and has a strong safety profile across different age groups. The global losartan potassium market, dominated by North America, sees significant contributions from Sandoz, with generic versions accounting for over 80% of the market revenue. Sandoz's entry into the market has enhanced affordability and accessibility, driving market growth. For detailed information, you can refer to the Sandoz Losartan product monograph.
Losar
Torrent Pharmaceuticals Limited is a prominent producer of losartan potassium, known for its extensive recall efforts to ensure product safety, such as the voluntary recall of losartan potassium tablets due to the detection of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA). The global losartan potassium API market, in which Torrent Pharmaceuticals participates, is projected to grow at a CAGR of 5.50% from 2024 to 2031, with North America holding over 40% of the global revenue. Losartan potassium from Torrent is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy, and nephropathy in Type 2 diabetic patients. Despite recalls, no adverse events have been reported, highlighting the company's commitment to safety. The market expansion is driven by increasing demand for hypertension management globally. For more details on their voluntary recall efforts, you can visit the FDA's official announcement.
Hyzaar
Hyzaar, a product from Merck, is a leading brand that combines losartan potassium with hydrochlorothiazide, offering effective treatment for hypertension and reducing the risk of stroke in certain patients. It is available in three tablet combinations: 50/12.5 mg, 100/12.5 mg, and 100/25 mg of losartan and hydrochlorothiazide, respectively. The 100mg/25mg dosage strength dominates the market, holding a 60% share as of 2022. North America accounts for over 40% of the global revenue, with the market expected to grow at a CAGR of 4.5% from 2024 to 2033. Hyzaar's efficacy is evident in clinical trials, where it showed significant reductions in blood pressure compared to losartan alone. For further details, visit the Hyzaar drug information page.
Losacar
Losartan Potassium, particularly the brand Losacar by Emcure Pharmaceuticals, is a leading choice in the global market due to its high efficacy and tolerability. The global Losartan Potassium API market, which includes brands like Losacar, is projected to grow at a CAGR of 5.50% from 2024 to 2031, reaching a market size of USD 2403.42 million by 2031. North America, where Losacar is widely used, holds over 40% of the global revenue, with a market size of USD 660.88 million in 2024. The increasing demand for antihypertensive medications, driven by the rising prevalence of hypertension and the growing geriatric population, further solidifies Losacar's position in the market. With its strong presence in regions like Asia Pacific, which is expected to grow at a CAGR of 7.5%, Losacar continues to be a preferred option for healthcare providers.
Angizaar
Angizaar, a brand of losartan potassium produced by Dr. Reddy's Laboratories, is renowned for its high quality and efficacy in treating hypertension and other heart conditions. As an angiotensin II receptor blocker (ARB), Angizaar works by blocking the action of angiotensin II, leading to relaxed blood vessels and improved blood flow. With a bioavailability of 25-35%, Angizaar is highly effective, and its active metabolite is 10 to 40 times more potent than losartan itself. In 2022, losartan was the eighth most commonly prescribed medication in the United States, highlighting its widespread use and trust in the medical community. Dr. Reddy's Laboratories ensures stringent quality control, making Angizaar a reliable choice for patients. For more detailed information on their Angizaar products, visit their official website.
Repace
Repace, a brand by Sun Pharmaceutical Industries, is a leading producer of losartan potassium, a crucial Angiotensin II receptor antagonist used to manage hypertension, protect kidney function in diabetic patients, and treat chronic heart failure. The global Losartan Potassium API market, in which Repace is a significant player, was estimated at USD 1652.2 million in 2024, with North America holding over 40% of the global revenue. Repace 25mg and 50mg+12.5mg formulations are widely used, with the latter combining losartan potassium with hydrochlorothiazide for enhanced blood pressure management. The market is expected to grow at a CAGR of 5.50% from 2024 to 2031, indicating a strong demand for losartan-based medications. Repace's products are available through various pharmaceutical companies, ensuring widespread accessibility. For more details on their formulations, visit their official product page.
Xartan
Weimer Pharma's Xartan is renowned as one of the top producers of losartan potassium, leveraging advanced manufacturing processes to ensure high-quality and consistent drug delivery. The global losartan potassium API market, which includes Xartan, is projected to grow at a CAGR of 5.50% from 2024 to 2031, with North America holding over 40% of the global revenue in 2024. Xartan's formulations, such as those using Ethocel polymers, exhibit pseudo-zero-order kinetics, enhancing patient compliance with once-a-day dosing. The market size for losartan potassium API is estimated at USD 1652.2 million in 2024, with significant growth anticipated in the Asia-Pacific region. Xartan's commitment to pharmaceutical innovation and quality contributes to its strong market presence. For more information, visit their official website.
Zefarin
Zefarin, a product from Ipca Laboratories, is renowned for its high-quality losartan potassium, a crucial medication for managing hypertension and other cardiovascular conditions. The global losartan potassium API market, which includes products like Zefarin, is projected to grow at a compound annual growth rate (CAGR) of 5.50% from 2024 to 2031, with the global market size estimated at USD 1652.2 million in 2024. North America holds a significant market share, over 40% of the global revenue, highlighting the demand for such medications. Ipca Laboratories, with its stringent manufacturing processes, ensures the production of polymorphic Form I of losartan potassium, which is crucial for its efficacy. The company's commitment to quality and compliance with regulatory standards makes Zefarin a trusted choice in the pharmaceutical industry.
Leave a Reply
Your email address will not be published.